Colorectal cancer (CRC), more commonly called colon cancer, is currently the second-leading cause of cancer-related death in the U.S. But studies find it’s also highly treatable, especially if it’s ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding that the Shield blood-based ...

The U.S. Food and Drug Administration on Monday approved a new blood test that can spot colon cancer. In late May, an FDA advisory panel had voted 7-2 that the benefits outweigh the risks when using ...

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a ...